Avascular necrosis in sickle cell (homozygous S) patients: Predictive clinical and laboratory indices by Madu, AJ et al.
86 Nigerian Journal of Clinical Practice • Jan-Feb 2014 • Vol 17 • Issue 1
Original Article
Abstract
Background: Pathogenetic mechanism as well as laboratory and clinical correlates of osteonecrosis in sickle cell have 
not been fully investigated. The aim of this study is to investigate the predictive value of the steady state white cell and 
platelet count as well as the frequency of bone pain crisis per annum to detect sickle cell patients who will eventually 
develop avascular necrosis (AVN).
Patients and Methods: A 5 year retrospective analysis of 122 homozygous S (HbSS) patients, aged 6-49 years (mean 
age 24.7 ± 7 years), out of which 16 patients (13.1%) had developed AVN within the years under review.
Results: The prevalence of AVN in sickle cell patients was determined to be 13.1 per 1000. The steady state white 
cell count, platelet count, frequency of bone pain crisis and hematocrit, was compared in patients that develop AVN 
and those who had not over the period. Only the steady state platelet count was found to differ significantly (P = 0.011) 
between these two patient groups and to correlate positively (Pearson correlation coefficient = −0.251) with development 
of AVN. The hematocrit, white cell count, and frequency of bone pain crisis were found neither to differ significantly nor 
correlate with the development of AVN.
Conclusion: In conclusion, patients with a raised steady state platelet count may have a higher tendency to develop 
AVN and may require closer orthopedic review and prophylactic intervention.
Key words: Avascular necrosis, homozygous S, platelet count, sickle cell anemia, white cell count
Date of Acceptance: 24-Apr-2013
Introduction
Avascular necrosis (AVN) is a debilitating and life‑changing 
complication of sickle cell disease and its prevalence 
ranges from 3.2% to 26.7% in this group of patients.[1‑3] 
The prevalence of healthy carriers (sickle cell trait) ranges 
between 10% and 40% across equatorial Africa and 
decreases to between 1% and 2% in Northern Africa and 
less than 1% in Southern Africa.[4] In West African countries 
such as Ghana and Nigeria, the frequency of the carrier state 
is 15‑30% while in East African countries such as Uganda 
and Tanzania, it shows wide variations of up to 45% in some 
areas.[5,6] In Nigeria, with an estimated carrier prevalence 
of 24%, 20/1000 births are estimated to be affected by 
sickle cell disease (SCD) resulting in 150,000 children with 
SCD born annually in Nigeria. About 300,000 children 
are born annually world‑wide with sickle cell disease with 
Nigeria accounting for one‑third of this population.[3]About 
1.2 million people are affected while India has the highest 
number of affected people in any one country.
AVN is a well‑recognized complication of sickle cell disease 
observed by Graham as early as 1924. The exact mechanism 
of this complication has not been fully explained; however, 
micro‑vascular occlusion from hypoxia induced erythrocyte 
sickling, along with extra‑vascular compression of the 
intra‑osseous blood supply caused by marrow hyperplasia 
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and hypertension results in ischemia, which culminates in 
bone infarction.[7] Raised hematocrit, low hemoglobin F, 
co‑existence of alpha thalassemia trait and frequent 
episodes of vaso‑occlusive crisis have all been shown to 
be positively correlated with AVN [7‑9] The importance 
of blood components, such as white cells and platelets in 
the pathogenesis of vaso‑occlusion and severity of sickle 
cell disease has been reported. It is then necessary to 
investigate how these parameters relate with prevalence of 
complications such as AVN.
Previous studies have all been prospective and have 
compared values in sickle patients with healthy controls 
while others have been cross‑sectional and focused on one 
of assessment of parameters between sickle cell patients who 
already had or did not have AVN,[10,11] in which case it may 
be difficult to discern whether these are the causes or effects 
of this complication. The importance of a retrospective study 
in this instance provides information on the pre‑morbid 
parameters as well as a better epidemiological assessment.
Predictive laboratory or clinical parameters, which correlate 
positively will help the physician to tailor preventive 
measures toward at risk patients. Furthermore, these may 
serve as targets for prophylactic therapeutic interventions, 
whose advantage cannot be underestimated in reducing the 
incidence of this life‑long debilitating complication.
Patients and Methods
This was a 6 year retrospective study of all patients seen at the 
sickle cell clinic of the University of Nigeria Teaching Hospital 
from 1st of January 2005 to the 1st of January 2010. Approval 
was obtained from the Ethics Committee of the hospital. 
Data at steady state was extracted from the hospital records. 
Patients who were not homozygous S (HbSS) on hemoglobin 
electrophoresis were excluded from the study. Data analyzed 
included age, sex, presence AVN, frequency of bone pain 
crisis per annum and steady state hematocrit, white cell, 
and platelet counts. Furthermore, the case note was used to 
ascertain those that had developed AVN in the period under 
review. Diagnosis of AVN was confirmed by the Radiologist 
and Orthopedic Surgeon using the plain radiographs of the 
affected hip. Excluded from the study were those who had 
developed AVN at presentation (this was to avert a possible 
confounding effect of AVN‑associated increase in these 
parameters) or were not HbSS. The correlation between 
frequency of vaso‑occlusive crisis, platelet, and white cell 
count and development of AVN was then computed.
Statistics
The aim of this study is to determine the predictive value 
of a high white cell and platelet count with regards to the 
risk of developing AVN in this patient group. Other clinical 
and laboratory variables; number of crises per annum and 
hemoglobin concentration were also collated. Pearson’s 
correlation co‑efficient (two‑tailed) was then obtained for 
each variable and presented in a tabular form. The P value 
was taken for all values < 0.05. Analysis was carried out 
with the Statistical Package for the Social Sciences (SPSS 
United Kingdom 2009) for windows version 17.0 package. 
Ethical clearance was obtained from the University of 
Nigeria Teaching Hospital Ethical Committee.
Results
The case notes of122 patients who were seen in the clinic 
during the period under review were pooled and relevant data 
were extracted. They were 69 males (56.6%) and 53 (43.4%) 
females, giving a ratio of 1.3:1. The patients were aged 
6‑49 years at presentation with a mean age of 24.7 ± 7.1 years 
and median age of 23 years. A total of 58 (47.5%) patients 
were aged 21‑30 years while 37 (30.3%) patients were aged 
11‑20 years. A total of 23 (18.9%) were aged 31‑40 years while 
two (1.6%) patients each were aged 10 years or below and 
41‑50 years respectively. The prevalence of AVN was found 
to be 13.1/1000 amongst sickle cell patients.
The mean white cell count was observed to be 13.5 ± 8.8 × 109/L 
and median value was 11.8 × 109/L (n = 101), the 
mean hematocrit was found to be 22 ± 5.5%, with a 
median value of 22% (n = 83), and the mean platelet 
count was 326 ± 145 × 109/L, and the median was 
328 × 109/L (n = 114). A total of 79 of the respondents 
had bone pain crises in the last 5 years and the average 
frequency was 3.8 episodes/annum. Frequency of bone pain 
crises was plotted against white cell count in those that had 
AVN and those that had none [Figure 1], and shows no 
graphical relationship between a high white cell count and 
pre‑disposition to AVN. Figure 2 shows a similar boxplot 
of the frequency of bone pain against platelet count in both 
Figure 1: Relationship between white cell count/frequency of 
crises/avascular necrosis
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patient that did and did not develop AVN and reveals a 
positive relationship between high steady state platelet 
count and pre‑disposition to AVN. Correlation co‑efficient 
was evaluated in both patient groups with respect to their 
steady state white cell and platelet count as well as frequency 
of bone pain crises per annum and is shown in Table 1.
A total of 23 patients (18.9%) were found to have bone 
and joint involvement in sickle cell disease in this study. 
9 (39.1%) were females while 14 (60.9%) were males. 
Sixteen patients (13.1%) had AVN of the hip involving 
19 hips with 3 patients having bilateral hip involvement. 
AVN was not noticed in any other joint. Left hip affectation 
was more common (52.6%) than right hip involvement. 
Majority (73.7%) of the cases of AVN of the hip was seen 
in patients aged 21‑30 years. Only three cases were noted 
in patients aged 31‑40 years. The rest occurred in patients 
aged 11‑20 years.
Discussion
The current patho‑physiologic mechanism of vaso‑occlusion 
in sickle cell disease has been found to involve the white cells 
and platelets as well as the expression of their inter‑cellular 
adhesion molecules. The relationship between the white 
cell and platelet counts with disease severity in sickle cell 
has also been observed in previous studies.[12] However, the 
relationship between the incidence of illness complications 
such as AVN and patient’s clinical parameters remain vague. 
A high platelet count was observed to positively correlate 
with a tendency to develop AVN. The role of platelets in 
the pathogenesis of vaso‑occlusion has been described; 
however, chronic complications like AVN, may involve 
irreversible thrombogenesis. it is known that depletion of 
platelets as well as white cell count, result in reduction of 
frequency of bone pain. The importance of our findings lies 
in the possible prevention of AVN using platelet‑depleting 
or regulating agents.
Other factors, which had been associated with development 
of AVN include a high hematocrit;[13] however, this was not 
supported by the findings of our study as well as a study done 
by [1,11] Disease severity has been expressed in s most studies 
to correlate with a raised white cell count;[5,6] however, it 
seems development of some of the complications of sickle 
cell like AVN as well as cerebrovascular accidents do not 
have a direct relationship to it. Our study did not reveal any 
significant difference between the rise in white cell count 
and development of AVN.
The group with AVN had a higher frequency of bone 
pain crisis, though this was not significantly different 
from those who did not. This is not supported by previous 
study; however, this may be an indication that AVN is 
sickle cell has a different pathogenetic mechanism from 
vaso‑occlusion. The frequency of bone pain has been 
observed to be an indicator of disease severity, in previous 
studies done the number of patients were less than that of 
this study and might not have been representative of the 
overall patient population.
This study has shown a close relationship between a high 
steady state platelet count and the development of AVN. 
Further studies are needed to investigate the thrombotic 
occlusion seen in AVN as it may not necessarily be 
vaso‑occlusive. Possible therapeutic intervention may be 
targeted at the platelet‑thrombin component as a preventive 
modality for patients at risk.
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